title: Highly stable, ligand-clustered "patchy" micelle nanocarriers for systemic tumor targeting.
abstract: A novel linear-dendritic block copolymer has been synthesized and evaluated for targeted delivery. The use of the dendron as the micellar exterior block in this architecture allows the presentation of a relatively small quantity of ligands in clusters for enhanced targeting, thus maintaining a long circulation time of these "patchy" micelles. The polypeptide linear hydrophobic block drives formation of micelles that carry core-loaded drugs, and their unique design gives them extremely high stability in vivo. We have found that these systems lead to extended time periods of increased accumulation in the tumor (up to 5 days) compared with nontargeted vehicles. We also demonstrate a fourfold increase in efficacy of paclitaxel when delivered in the targeted nanoparticle systems, while significantly decreasing in vivo toxicity of the chemotherapy treatment.
  
  
  BACKGROUND
  A micellar vehicle using dendrons as the exterior block in combination with a polypeptide hydrophobic block was shown to incorporate and deliver paclitaxel to xenograft tumors with a four-fold increase in efficacy and reduced toxicity.
authors.affiliation: Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Poon
authors.forename: Jung Ah
authors.initials: JA
authors.lastname: Lee
authors.forename: Shenwen
authors.initials: S
authors.lastname: Huang
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Prevost
authors.forename: Paula T
authors.initials: PT
authors.lastname: Hammond
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000378:metabolism / Q000627:therapeutic use*; D004355:Drug Stability; D006801:Humans; D007275:Injections, Intravenous; D008024:Ligands; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008823:Micelles; D050997:Nanomedicine; D053758:Nanoparticles / Q000627:therapeutic use*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008024:Ligands; D008823:Micelles; D017239:Paclitaxel
references.citation: Br J Cancer. 2007 Jul 16;97(2):170-6
references.pmid: 17595665
references.citation: Mol Pharm. 2008 Jul-Aug;5(4):505-15
references.pmid: 18672949
references.citation: Science. 2003 Apr 25;300(5619):615-8
references.pmid: 12714738
references.citation: Adv Drug Deliv Rev. 2004 Apr 29;56(8):1161-76
references.pmid: 15094213
references.citation: Biochemistry. 1994 Aug 2;33(30):8941-7
references.pmid: 7913831
references.citation: Nat Biotechnol. 2005 Dec;23(12):1517-26
references.pmid: 16333296
references.citation: Gene Ther. 2002 Nov;9(22):1542-50
references.pmid: 12407426
references.citation: Breast Cancer Res Treat. 2008 Mar;108(2):241-50
references.pmid: 17476588
references.citation: N Engl J Med. 1995 Apr 13;332(15):1004-14
references.pmid: 7885406
references.citation: Colloids Surf B Biointerfaces. 2005 Oct 10;45(2):82-9
references.pmid: 16144761
references.citation: Blood. 1999 Jun 1;93(11):3940-8
references.pmid: 10339503
references.citation: Curr Pharm Biotechnol. 2005 Apr;6(2):131-50
references.pmid: 15853692
references.citation: J Control Release. 2000 Mar 1;65(1-2):271-84
references.pmid: 10699287
references.citation: J Pharmacokinet Biopharm. 1973 Apr;1(2):123-36
references.pmid: 4764426
references.citation: Cancer Metastasis Rev. 2007 Mar;26(1):141-52
references.pmid: 17333345
references.citation: J Biol Chem. 1996 Nov 8;271(45):28024-30
references.pmid: 8910412
references.citation: Pharm Res. 2004 Dec;21(12):2153-7
references.pmid: 15648245
references.citation: Langmuir. 2008 May 20;24(10):5213-7
references.pmid: 18257595
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3708-16
references.pmid: 15173077
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20
references.pmid: 16606824
references.citation: Clin Cancer Res. 2001 Feb;7(2):223-5
references.pmid: 11234871
references.citation: Langmuir. 2006 Apr 11;22(8):3570-8
references.pmid: 16584228
references.citation: Cancer Res. 1998 Jun 1;58(11):2404-9
references.pmid: 9622081
references.citation: J Control Release. 2001 May 14;72(1-3):191-202
references.pmid: 11389998
references.citation: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references.pmid: 18758474
references.citation: Mol Pharmacol. 2004 Dec;66(6):1406-14
references.pmid: 15371560
references.citation: J Control Release. 2004 Apr 28;96(2):273-83
references.pmid: 15081218
references.citation: J Cell Sci. 2000 May;113 ( Pt 10):1677-86
references.pmid: 10769199
references.citation: Clin Cancer Res. 2008 Dec 15;14(24):8161-8
references.pmid: 19088031
references.citation: Science. 2004 Mar 19;303(5665):1818-22
references.pmid: 15031496
references.citation: Cancer Res. 2005 Jun 15;65(12):5317-24
references.pmid: 15958579
references.citation: Adv Drug Deliv Rev. 2000 Mar 30;41(2):147-62
references.pmid: 10699311
references.citation: Anal Biochem. 2005 Mar 15;338(2):284-93
references.pmid: 15745749
references.citation: Cancer Res. 2006 Jul 1;66(13):6732-40
references.pmid: 16818648
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2586-91
references.pmid: 18272481
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6551-9
references.pmid: 14695160
references.citation: Nat Rev Drug Discov. 2003 May;2(5):347-60
references.pmid: 12750738
references.citation: Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54
references.pmid: 17875985
references.citation: Angew Chem Int Ed Engl. 2006 Feb 13;45(8):1198-215
references.pmid: 16444775
references.citation: Science. 1994 Mar 18;263(5153):1600-3
references.pmid: 8128245